Dr. Juneyoung Lee received his PhD from the Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences at The University of Tokyo in 2016. Dr. Lee studied mucosal immunology in Dr. Hiroshi Kiyono’s laboratory in the Division of Mucosal Immunology, Department of Microbiology and Immunology at the Institute of Medical Science, The University of Tokyo. In 2016, he joined Dr. Louise McCullough’s laboratory in the Department of Neurology at McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth Houston) as a postdoctoral research fellow. During his postdoctoral training, Dr. Lee investigated the regulatory mechanisms of the microbiome-gut-brain axis in aging and stroke. He was awarded a Postdoctoral Fellowship and the prestigious Lawrence M. Brass Stroke Research Award from the American Heart Association (AHA) and the American Brain Foundation. Very recently, he was awarded a Career Development Award from the AHA and the UT Rising STARs Award from the University of Texas that support his new independent research program, “Neuro-Mucosal Immunology”. In 2021, Dr. Lee was appointed as an Assistant Professor in the Department of Neurology, McGovern Medical School at UTHealth Houston. Dr. Lee’s Laboratory is currently investigating therapeutic strategies for age-related neurological diseases and psychosocial stress by modulating microbial, metabolomic, immunological and metabolic profiles in the host.
Dr. Lee’s Laboratory of Neuro-Mucosal Immunology explores (1) neuro-immune interactions, (2) host-microbe interactions, (3) inter-organ communication and (4) host metabolism. Specifically, these interdisciplinary studies include investigating the bidirectional communication between the brain, host mucosal tissues (e.g., gastrointestinal, respiratory and urogenital tracts) and metabolic tissues (e.g., liver and adipose tissues) in the context of age-related neurological diseases and psychosocial stress. The Lee Laboratory aims to interrogate the unknown mechanisms and target dysregulation in diseases with the goal of identifying novel therapeutic options by utilizing state-of-art techniques for metagenomics (e.g., microbiome), metabolomics and flow cytometry. Very recently, the Lee Laboratory has also established two experimental platforms within the laboratory for translational and innovative research: (1) patient induced pluripotent stem cells (iPSCs)-derived organoids and assembloids and (2) single-cell and spatial transcriptomics and related key instruments for single-cell RNA sequencing study.